Only national nuclear pharmacy network to offer Myoview™, Cardiolite® and generic sestamibi
DUBLIN, Ohio, June 12, 2009 — Cardinal Health, a global provider of products and services that improve the safety and productivity of health care, today unveiled an expanded portfolio of cardiac imaging agent products that offers Myoview™, Cardiolite® and a new generic sestamibi product from Cardinal Health.
The company announced the product portfolio expansion as part of its strategy to broaden choice for its customers. Beginning this summer, Cardinal Health customers can choose the technetium heart agent that best fits their patients’ clinical needs and the economic profiles of their imaging practices.
“Cardinal Health is now the only company that can offer all three technetium-based heart agents across a national network of nearly 160 nuclear pharmacies,” said John Rademacher, president and general manager of Nuclear and Specialty Pharmacy Services for Cardinal Health. “By increasing choice for our customers, we continue to add differentiated value from our industry leading foundation of service and quality. Although we recognize the serious implications of the current global molybdenum shortage, we believe the introduction of this additional product is an important long-term benefit for nuclear medicine practitioners and their patients. Cardinal Health will continue to work with industry leaders and the Society for Nuclear Medicine to address current, mid-range and long-term solutions for molybdenum supply.”
The company is highlighting the expanded product portfolio at the 2009 Society of Nuclear Medicine Annual Meeting being held June 13-17 in Toronto.
Cardinal Health operates the largest radiopharmacy network in the United States, with nearly 160 nuclear pharmacy locations that compound and dispense radiopharmaceuticals that aid in the early detection and treatment of disease. The company also operates 27 cyclotrons that support the dispensing of PET products from more than 90 of its nuclear pharmacy locations, including dispensing of novel agents for use in clinical trials. The combination of nuclear pharmacy expertise and the size of its network allows Cardinal Health to reach more than 85 percent of all U.S. hospitals within three hours and also provides service and clinical expertise to the nuclear medicine community. Cardinal Health is also the largest employer of nuclear pharmacists in the world.
About Cardinal Health
Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is a $91 billion, global company serving the health care industry with products and services that help hospitals, physician offices and pharmacies reduce costs, improve safety, productivity and profitability, and deliver better care to patients. With a focus on making supply chains more efficient, reducing hospital-acquired infections and breaking the cycle of harmful medication errors, Cardinal Health develops market-leading technologies, including Alaris® IV pumps, Pyxis® automated dispensing and patient identification systems, MedMined™ electronic infection surveillance service and VIASYS® respiratory care products. The company also manufactures medical and surgical products and is one of the largest distributors of pharmaceuticals and medical supplies worldwide. Ranked No. 18 on the Fortune 500, Cardinal Health employs more than 40,000 people on five continents. More information about the company may be found at cardinalhealth.com.
